
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Inovio Pharmaceuticals. The associated price target remains the same with $5.00. Ram Selvaraju’s rating is based on several
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| INO | Inovio Pharmaceuticals | 1.63 | -0.02 | -1.16% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.63 | -1.16% |

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Inovio Pharmaceuticals. The associated price target remains the same with $5.00. Ram Selvaraju’s rating is based on several

Inovio (INO) announced that it has submitted a Conditional Marketing Authorization application to the European Medicines Agency for voceryq, previously referred to as INO-3107, as a treatment for adults with

Inovio Pharmaceuticals ( ($INO) ) just unveiled an announcement. Effective November 13, 2026, Inovio Pharmaceuticals increased its board from eight to nine directors and appointed Jeffrey Libson to the newly

Latest data shows the largest indicative borrow rate increases among liquid option names include: Armada Acquisition Corp II (XRPN) 96.07% +7.25, Leverage Shares 2X Long SK Hynix Daily ETF (SKHX)

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Inovio Pharmaceuticals. The associated price target remains the same with $5.00. Ram Selvaraju’s rating is based on several

Inovio Pharmaceuticals (($INO)) has held its Q3 earnings call. Read on for the main highlights of the call. Inovio Pharmaceuticals’ earnings call carried a strongly positive tone after the FDA

Piper Sandler lowered the firm’s price target on Inovio (INO) to $6 from $8 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with

As of September 30, 2026, cash, cash equivalents and short-term investments were $48.4 million (excluding net proceeds from the November 2026 offering of approximately $80.5 million), compared to $58.5 million

Pre-earnings options volume in Inovio (INO) is normal with calls leading puts 21:1. Implied volatility suggests the market is anticipating a move near 10.7%, or 15c, after results are released.

Here’s a look at today’s key earnings reports from major publicly traded companies. Quantum computing and AI infrastructure will be in focus as several companies report results after large contract
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $320.29M | $-0.13 | $50.00K | 0.02 | -2.15 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.